help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shoupe, D.
Right arrow Articles by Lobo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoupe, D.
Right arrow Articles by Lobo, R. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL
*ESTROGENIC SUBSTANCES, CONJUGATED
*ESTRONE
*MEDROXYPROGESTERONE
*NALOXONE

Journal of Clinical Endocrinology & Metabolism, Vol 60, 178-183, Copyright © 1985 by Endocrine Society


ARTICLES

The effects of estrogen and progestin on endogenous opioid activity in oophorectomized women

D Shoupe, FJ Montz and RA Lobo

Sex steroids may modulate the secretion of beta-endorphin (beta-EP). Naloxone (Nal), an opioid antagonist, has been used as a probe of central opioid activity. Nal-evoked responses of PRL and LH were evaluated in the midluteal (ML) and late follicular (LF) phases of ovulatory women (Pre) and compared to responses of oophorectomized women before and after the administration of conjugated estrogens (CE) and again after CE and progestin administration. In the ML and LF phases, serum LH increased significantly (P less than 0.05 and P less than 0.01, respectively) during Nal infusion for 4 h, while PRL did not change. In oophorectomized women, there were no significant changes in LH or PRL during Nal infusion. After 3 weeks of CE treatment (1.25 mg daily), LH increased during Nal infusion (P less than 0.05), as did PRL (P less than 0.01). After treatment with CE and medroxyprogesterone acetate (MPA), LH and PRL both increased (P less than 0.05 and P less than 0.01, respectively). The area under the LH curve during Nal infusion after CE and MPA treatment was greater than that after CE alone. Both of these responses were comparable to those of the LF and ML phases of Pre women. During Nal infusion, LH pulse frequency increased in the ML compared to the LF phase of the cycle and, in oophorectomized women, was greater after CE and CE with MPA treatment compared to pretreatment values (P less than 0.05). LH amplitudes during Nal infusion were highest in the ML phase and after CE and MPA treatment in oophorectomized women, and these LH amplitudes were similar. No correlation was found between peripheral plasma beta-EP and Nal-evoked LH responses. No differences were evident in plasma beta-EP levels between Pre and oophorectomized women. In conclusion, 1) endogenous opioid activity is low in oophorectomized women; 2) treatment with estrogen increases opioid activity, and the addition of a progestin increases this activity further; and 3) these data support the contention that sex steroids exert a profound influence on endogenous opioid activity.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
Y. R. Smith, J.-K. Zubieta, M. G. del Carmen, R. F. Dannals, H. T. Ravert, H. A. Zacur, and J. J. Frost
Brain Opioid Receptor Measurements by Positron Emission Tomography in Normal Cycling Women: Relationship to Luteinizing Hormone Pulsatility and Gonadal Steroid Hormones
J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4498 - 4505.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. P. Cemeroglu, G. B. Kletter, W. Guo, M. B. Brown, R. P. Kelch, J. C. Marshall, V. Padmanabhan, and C. M. Foster
In Pubertal Girls, Naloxone Fails to Reverse the Suppression of Luteinizing Hormone Secretion by Estradiol
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3501 - 3506.
[Abstract] [Full Text]


Home page
Reproductive SciencesHome page
A. J. Rapkin, D. Shoupe, A. Reading, K. K. Daneshgar, L. Goldman, Y. Bohn, D. W. Brann, and V. B. Mahesh
Decreased Central Opioid Activity in Premenstrual Syndrome: Luterinizing Hormone Response to Naloxone
Reproductive Sciences, March 1, 1996; 3(2): 93 - 98.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society